Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03333551 · ClinicalTrials.gov registry record · Phase 4
Cardiac Uptake of 18F Florbetapir in Patients Undergoing Chemotherapy
A Phase 4 study, sponsored by Medical College of Wisconsin.
- Terminated
- Registry status
- Phase 4
- Development phase
- 3
- Enrollment target
NCT03333551 is a Phase 4 study that was terminated before completion, run by Medical College of Wisconsin. The registered enrollment target is 3 participants.
The verdict
NCT03333551, a Phase 4 study, was terminated before completion, sponsored by Medical College of Wisconsin.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 3 participants
- Enrollment target
Study Summary
This is a pilot study designed to assess for relative change in cardiac 18F Florbetapir uptake in patients with AL cardiac amyloidosis after appropriate chemotherapy.
Interventions
- DRUG F18 Florbetapir (amyvid) cardiac PET/CT imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2020-10-01 |
| Est. Completion | 2023-05-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03333551
The ClinicalTrials.gov registry entry for NCT03333551 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which F18 Florbetapir (amyvid) cardiac PET/CT imaging is the first listed.
NCT03333551 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03333551 about?
NCT03333551 is a clinical study titled "Cardiac Uptake of 18F Florbetapir in Patients Undergoing Chemotherapy". This is a pilot study designed to assess for relative change in cardiac 18F Florbetapir uptake in patients with AL cardiac amyloidosis after appropriate chemotherapy.
What is the current status of trial NCT03333551?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 3 participants. The study started on 2020-10-01. Estimated completion is 2023-05-08.
What interventions are being tested in trial NCT03333551?
The interventions under investigation include: F18 Florbetapir (amyvid) cardiac PET/CT imaging (DRUG).
Who is sponsoring clinical trial NCT03333551?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.